A Self‐Digitization Dielectrophoretic (SD‐DEP) Chip for High‐Efficiency Single‐Cell Capture, On‐Demand Compartmentalization, and Downstream Nucleic Acid Analysis

Qin, Yuling; Li, Wu; Schneider, Thomas; Yen, Gloria S.; Wang, Jiasi; Xu, Shihan; Li, Min; Paguirigan, Amy L.; Smith, Jordan L.; Radich, Jerald P.; Anand, Robbyn K.; Chiu, Daniel T.

doi:10.1002/anie.201807314

Cited by 34 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To fully characterize the whole transcriptome profile and pathway regulation in metastatic CTCs, single-cell RNA-sequencing (scRNA-seq) has been applied to few CTCs picked by capillary suction and dielectrophoretic microfluidics with the cells labelled by fluorescent staining 2,12–14 . Nevertheless, these techniques are constrained by their limited throughput and reliance upon antibody-based marker expression.…”

Section: Introductionmentioning

confidence: 99%

Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells

et al. 2019

View full text Add to dashboard Cite

Molecular analysis of circulating tumor cells (CTCs) at single-cell resolution offers great promise for cancer diagnostics and therapeutics from simple liquid biopsy. Recent development of massively parallel single-cell RNA-sequencing (scRNA-seq) provides a powerful method to resolve the cellular heterogeneity from gene expression and pathway regulation analysis. However, the scarcity of CTCs and the massive contamination of blood cells limit the utility of currently available technologies. Here, we present Hydro-Seq, a scalable hydrodynamic scRNA-seq barcoding technique, for high-throughput CTC analysis. High cell-capture efficiency and contamination removal capability of Hydro-Seq enables successful scRNA-seq of 666 CTCs from 21 breast cancer patient samples at high throughput. We identify breast cancer drug targets for hormone and targeted therapies and tracked individual cells that express markers of cancer stem cells (CSCs) as well as of epithelial/mesenchymal cell state transitions. Transcriptome analysis of these cells provides insights into monitoring target therapeutics and processes underlying tumor metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a publication from the same group, DEP-based cell trapping and manipulation were combined with gene expression analysis. 191 Here, K562 leukemia cells were injected into one of two main PDMS microchannels, lined with a thin film metallic electrode. Using the electrodes, an electric field was generated to trap cells based on DEP (single-cell capture efficiency of 91.7%).…”

Section: Microfluidicsmentioning

confidence: 99%

Chemical Analysis of Single Cells and Organelles

Nguyen

Rabasco

et al. 2020

Anal. Chem.

View full text Add to dashboard Cite

“…Recently, Chiu and colleagues developed a microfluidics-based chip for nucleic acid manipulation and analysis in single cells. Such chip could be adopted to detect genetic mutations responsible for resistance and relapse of individual AML patients for personalised medicine approaches [ 177 ].…”

Section: Does the Promise Hold?mentioning

confidence: 99%

Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?

Valli¹,

Gruszka-Westwood²,

Alcalay³

2020

JCM

View full text Add to dashboard Cite

Drug repurposing is a method of drug discovery that consists of finding a new therapeutic context for an old drug. Compound identification arises from screening of large libraries of active compounds, through interrogating databases of cell line gene expression response upon treatment or by merging several types of information concerning disease–drug relationships. Although, there is a general consensus on the potential and advantages of this drug discovery modality, at the practical level to-date no non-anti-cancer repurposed compounds have been introduced into standard acute myeloid leukaemia (AML) management, albeit that preclinical validation yielded several candidates. The review presents the state-of-the-art drug repurposing approach in AML and poses the question of what has to be done in order to take a full advantage of it, both at the stage of screening design and later when progressing from the preclinical to the clinical phases of drug development. We argue that improvements are needed to model and read-out systems as well as to screening technologies, but also to more funding and trust in drug repurposing strategies.

show abstract

A Self‐Digitization Dielectrophoretic (SD‐DEP) Chip for High‐Efficiency Single‐Cell Capture, On‐Demand Compartmentalization, and Downstream Nucleic Acid Analysis

Cited by 34 publications

References 44 publications

Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells

Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells

Chemical Analysis of Single Cells and Organelles

Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?

Contact Info

Product

Resources

About